🚀 VC round data is live in beta, check it out!
Akero Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Akero Therapeutics and similar public comparables like Eli Lilly, Johnson & Johnson, AbbVie, Roche and more.
Akero Therapeutics Overview
About Akero Therapeutics
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Founded
N/A
HQ
—
Employees
N/A
Website
N/A
Sectors
Financials (FY)
Market Cap
—
Akero Therapeutics Stock Performance
Akero Therapeutics has current market cap of —.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| — | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAkero Therapeutics Valuation Multiples
Akero Therapeutics Financial Valuation Multiples
As of March 11, 2026, Akero Therapeutics has market cap of —.
Equity research analysts estimate Akero Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 |
|---|
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Akero Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Akero Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eli Lilly | XXX | XXX | XXX | XXX | XXX | XXX |
| Johnson & Johnson | XXX | XXX | XXX | XXX | XXX | XXX |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| Novartis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akero Therapeutics M&A Activity
Akero Therapeutics acquired XXX companies to date.
Last acquisition by Akero Therapeutics was on XXXXXXXX, XXXXX. Akero Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Akero Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAkero Therapeutics Investment Activity
Akero Therapeutics invested in XXX companies to date.
Akero Therapeutics made its latest investment on XXXXXXXX, XXXXX. Akero Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Akero Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Akero Therapeutics
| Is Akero Therapeutics publicly listed? | Yes, Akero Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Akero Therapeutics? | Akero Therapeutics trades under AKRO ticker. |
| When did Akero Therapeutics go public? | Akero Therapeutics went public in 2019. |
| Who are competitors of Akero Therapeutics? | Akero Therapeutics main competitors are Eli Lilly, Johnson & Johnson, AbbVie, Roche. |
| Is Akero Therapeutics profitable? | No, Akero Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.